Fulcrum Reports Q1 2026 Earnings with Positive Trial Results and Financial Update
Fulcrum (FULC) reported Q1 2026 earnings with positive results from its PIONEER Phase Ib trial, showing improved fetal hemoglobin levels and reduced VOCs. The company also provided an update on its financial position, including a decrease in cash reserves and increased operating expenses.
Tickers: $FULC
Topics: anemia clinical trials financials hemoglobin pharmaceuticals